UPDATE : Monday, September 7, 2020
상단여백
HOME Pharma
LG Chem working on antidiabetic Zemiglo combo
  • By Lee Hye-seon
  • Published 2018.01.26 12:25
  • Updated 2018.01.26 12:25
  • comments 0

LG Chem is likely to develop an antidiabetic drug that combines DPP-4 (dipeptidyl peptidase-4) inhibitor Zemiglo and sodium-glucose cotransporter-2 (SGLT2) inhibitor.

The Ministry of Food and Drug Safety on Thursday approved LG Chem’s plan for a phase-1 clinical trial to evaluate drug interactions between Zemiglo and dapagliflozin or Zemiglo and empagliflozin. The study will involve 48 patients at Samsung Medical Center.

Zemiglo

AstraZeneca sells dapagliflozin under the trade name of Forxiga, and Boehringer Ingelheim, empagliflozin, under the name Jardiance. The two drugs are SGLT-2 inhibitors.

Physicians can prescribe the two drugs as a single therapy, or combine each with other treatments such as metformin, metformin+pioglitazone, metformin+sulfonylurea, insulin, insulin+metformin, insulin+metformin+ sulfonylurea, and DPP-4 inhibitor.

However, the combinations of SGLT-2 inhibitors with DPP-4 inhibitors are limited. Forxiga can be combined with Januvia and Jardiance with Trajenta.

Although the two SGLT-2 inhibitors cannot be combined with all DPP-4 inhibitors, LG Chem might be seeking to develop a combo of a DPP-4 inhibitor and an SGLT-2 inhibitor, observers said.

Recently, LG Chem has been concentrating on expanding lineups of Zemiglo combo drugs. After releasing a Zemiglo and metformin combo Gemimet, the company last year launched Zemiro, which merged a DPP-4 inhibitor with lipid reduction drug rosuvastatin.

It was the first time that such combination drug was released in the Korean market.

lhs@docdocdoc.co.kr

<© Korea Biomedical Review, All rights reserved.>

Other articles by Lee Hye-seon
iconMost viewed
Comments 0
More
Please leave the first comment.
여백
여백
여백
Back to Top